LOGIN  |  REGISTER
Cue Biopharma
Compass Therapeutics

Hologic to Announce Financial Results for the First Quarter of Fiscal 2024 on Thursday, February 1, 2024

January 04, 2024 | Last Trade: US$74.25 0.04 0.05

MARLBOROUGH, Mass. / Jan 04, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2024 on Thursday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 5909239. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins.

Hologic will provide a live and webcast replay of the call on the Company’s website at https://investors.hologic.com. The call will be available there for 30 days. The webcast replay will be available approximately two hours after the call ends.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Recursion

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB